Results 61 to 70 of about 2,622 (185)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 109-113, July 2026.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

Journal of Gastroenterology and Hepatology, Volume 41, Issue 7, Page 2006-2029, July 2026.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, Wan Chee Ong, Vineet Ahuja, Satimai Aniwan, Ryota Hokari, Wei Jie Jonathan Lee, Alex Hwong‐Ruey Leow, Wai‐Keung Leung, Wee‐Chian Lim, Govind Makharia, Katsuyoshi Matsuoka, Nazri Mustaffa, Siew‐Chien Ng, Mathew Philip, Pises Pisespongsa, Raja Affendi Raja Ali, Zhi Hua Ran, Marcellus Simadibrata, Jose Sollano, Malcolm Tan, Hang Dao Viet, Nik Razima Wan Ibrahim, Kai Chun Wu, Byong Duk Ye, Ida Hilmi, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD)   +34 more
wiley   +1 more source

Effects of hypnotic bromovalerylurea on microglial BV2 cells

Journal of Pharmacological Sciences, 2017
An old sedative and hypnotic bromovalerylurea (BU) has anti-inflammatory effects. BU suppressed nitric oxide (NO) release and proinflammatory cytokine expression by lipopolysaccharide (LPS)-treated BV2 cells, a murine microglial cell line.
Shun Kawasaki, Naoki Abe, Fumito Ohtake, Afsana Islam, Mohammed Emamussalehin Choudhury, Ryo Utsunomiya, Satoshi Kikuchi, Tasuku Nishihara, Jun Kuwabara, Hajime Yano, Yuji Watanabe, Mayuki Aibiki, Toshihiro Yorozuya, Junya Tanaka   +13 more
doaj   +1 more source

Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation

ACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, Volume 6, Issue 2, Page 94-104, June 2026.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi Tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL‐23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real‐life data are scant. We aimed to evaluate the effectiveness and safety of MIRI in a real‐world setting.
Giuseppe Costantino, Anna Viola, Andrea Iuculano, Fabio Salvatore Macaluso, Raffaele Li Voti, Maria Cappello, Chiara Antoci, Concetta Ferracane, Morena Sciuto, Domenico Catarella, Stefanie Parisi, Filippo Mocciaro, Barbara Scrivo, Maria Emanuela Distefano, Roberto Vassallo, Maria Giovanna Minissale, Giuseppe Scalisi, Serena Garufi, Sofia Rao, Stefano Muscarella, Vincenza Tortorella, Emiliano Giangreco, Marco Muscianisi, Ambrogio Orlando, Walter Fries   +24 more
wiley   +1 more source

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses

Rheumatology and Therapy, 2023
Filgotinib is an oral preferential Janus kinase 1 inhibitor that demonstrated significant reductions in radiographic progression, with an acceptable tolerability and safety profile, vs placebo in patients with rheumatoid arthritis (RA) and an inadequate ...
Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G. Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran   +6 more
doaj   +1 more source

Effect of filgotinib on health-related quality of life in active psoriatic arthritis:a randomized phase 2 trial (EQUATOR) [PDF]

, 2019
To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.
Ogdie, Alexis, Coates, Laura,, Tasset, C, Trivedi, Mona, Besuyen, R, Gossec, Laure, Tillett, W, Coates, LC, Tillett, William, Gossec, L, Hendrikx, Thijs, Meuleners, L, Leung, YY, Coates, Laura, Trivedi, M, Gao, Jingjing, Orbai, Ana-Maria, Meuleners, Luc, Coates, Laura C, Gao, J, Leung, Ying Ying, Besuyen, Robin, Ogdie, A, Tasset, Chantal, Orbai, A-M, Hendrikx, T   +25 more
core   +1 more source